United States securities and exchange commission logo





                             June 6, 2022

       Justin De Four
       Chief Executive Officer
       BioLife Sciences Inc.
       2831 St. Rose Parkway #200
       Henderson, NV 89052

                                                        Re: BioLife Sciences
Inc.
                                                            Offering Statement
on Form 1-A
                                                            Filed May 31, 2022
                                                            File No. 024-11898

       Dear Mr. De Four:

                                                        This is to advise you
that we do not intend to review your offering statement.

               We will consider qualifying your offering statement at your
request. In connection with
       your request, please confirm in writing that at least one state has
advised you that it is prepared
       to qualify or register your offering. If a participant in your offering
is required to clear its
       compensation arrangements with FINRA, please have FINRA advise us that
it has no objections
       to the compensation arrangements prior to qualification.

               We remind you that the company and its management are
responsible for the accuracy
       and adequacy of their disclosures, notwithstanding any review, comments,
action or absence of
       action by the staff.

                                                        Please contact Jason
Drory at 202-551-8342 with any questions.




                             Sincerely,


                             Division of Corporation Finance

                             Office of Life Sciences
       cc:                                              Jonathan Leinwand, Esq.